SLXN Initiates GMP Manufacturing of SIL204 with Catalent, Secures Helsinki Ethics Approval for Phase 2/3 KRAS‑Driven Pancreatic Cancer Trial
Silexion Therapeutics Corp Ordinary Shares · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.98
-50% in 3d after detection
Post-detection moves
1h
—
1d
-9.3%
3d
-50%
7d
-9.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS